Last $59.49 USD
Change Today +1.88 / 3.26%
Volume 2.9M
ISIS On Other Exchanges
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

isis pharmaceuticals inc (ISIS) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/19/14 - $67.12
52 Week Low
05/9/14 - $22.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

isis pharmaceuticals inc (ISIS) Related Businessweek News

View More BusinessWeek News

isis pharmaceuticals inc (ISIS) Details

Isis Pharmaceuticals, Inc. is engaged in the discovery and development of antisense drugs using novel drug discovery platform. The company’s flagship product includes the KYNAMRO injection, which is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia; and for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 31 drugs in development for the treatment of various diseases, including cardiovascular and metabolic diseases; severe and rare diseases, including neurological disorders; and cancer. The company has strategic alliances and collaboration agreements primarily with AstraZeneca AB, Biogen Idec MA Inc., Bristol-Myers Squibb, Eli Lilly and Company, Genzyme Corporation, GlaxoSmithKline, Hoffman-La Roche Inc., F. Hoffmann-La Roche Ltd., Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Excaliard Pharmaceuticals, Inc., iCo Therapeutics Inc., OncoGenex Technologies Inc., and Xenon Pharmaceuticals Inc. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.

365 Employees
Last Reported Date: 03/3/14
Founded in 1989

isis pharmaceuticals inc (ISIS) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $1.5M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $581.4K
Chief Operating Officer, Corporate Secretary,...
Total Annual Compensation: $1.2M
Senior Vice President of Antisense Research
Total Annual Compensation: $631.6K
Senior Vice President of Development
Total Annual Compensation: $624.4K
Compensation as of Fiscal Year 2013.

isis pharmaceuticals inc (ISIS) Key Developments

Isis Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients with Myotonic Dystrophy Type 1

Isis Pharmaceuticals, Inc. announced that it has initiated a study for ISIS-DMPKRx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the production of toxic dystrophia myotonica-protein kinase (DMPK) RNA in cells. ISIS-DMPKRx is specifically designed to reduce toxic DMPK RNA. DM1 is a rare genetic neuromuscular disease primarily characterized by progressive muscle atrophy, weakness and myotonia. The Phase 1/2 study is a randomized, placebo-controlled, dose-escalation study evaluating the safety and tolerability of ISIS-DMPKRx. The six-week study will evaluate multiple ascending doses of ISIS-DMPKRx in approximately 36 patients with DM1.

Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Isis Pharmaceuticals, Inc. announced final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXIRx is designed to reduce the production of Factor XI, a coagulation factor that plays a key role in thrombosis. ISIS-FXIRx-treated patients experienced a dose-dependent decrease in venous thromboembolic events. Patients treated with 300 mg of ISIS-FXIRx experienced a seven-fold lower rate of VTE as compared with those treated with enoxaparin (4.2% and 30.4%, respectively; p<0.001). Patients treated with 200 mg of ISIS-FXIRx had a rate of VTE comparable to that in patients treated with enoxaparin (26.9% and 30.4%, respectively). The rate of VTE in patients given enoxaparin is within the range documented in previous studies in this therapeutic setting. ISIS-FXIRx treatment was associated with a dose-dependent and sustained reduction in Factor XI activity that correlated with the lower rate of VTE. The rate of bleeding was low with ISIS-FXIRx and enoxaparin. The Phase 2 study of ISIS-FXIRx in 293 patients undergoing TKA was a global, multi-center, open-label, comparator-controlled study comparing ISIS-FXIRx with enoxaparin. Patients in the ISIS-FXIRx-treated groups received either 200 mg or 300 mg of ISIS-FXIRx for six weeks prior to TKA surgery and six hours and three days after surgery. Patients in the enoxaparin group received 40 mg of enoxaparin the evening before surgery, and once daily thereafter for at least eight days. All patients underwent mandatory bilateral venography to detect deep vein thrombosis. Venograms and suspected bleeding events were evaluated by a blinded independent adjudication committee. In this study, ISIS-FXIRx was well tolerated. There were no observed differences in safety outcomes compared with enoxaparin. In particular, there were no flu-like symptoms, and injection site reactions were infrequent and mild. There have been no drug-related serious adverse events reported to date. The Phase 2 study was published ahead of print and on-line in The New England Journal of Medicine on Sunday, December 7, 2014.

Isis Pharmaceuticals, Inc. Initiates Phase 3 Study of ISIS-SMN Rx in Children with Spinal Muscular Atrophy

Isis Pharmaceuticals, Inc. announced the initiation of a pivotal Phase 3 study evaluating ISIS-SMN(Rx) in approximately 120 non-ambulatory children with spinal muscular atrophy (SMA). SMA is a severe and rare genetic neuromuscular disease characterized by muscle atrophy and weakness. The Phase 3 study, CHERISH, is the second Phase 3 study Isis has initiated in a global late-stage clinical development program for ISIS-SMN(Rx). Isis earned a $27 million milestone payment from its development partner, Biogen Idec, for the dosing of the first patient in this study. Isis is also evaluating ISIS-SMN(Rx) in the Phase 3 study, ENDEAR, in infants with SMA. Isis is conducting both Phase 3 studies with agreement from the U.S. Food and Drug Administration (FDA) for special protocol assessments, or SPAs. CHERISH, a Phase 3 study of ISIS-SMN(Rx,) is a randomized, double-blind, sham-procedure controlled fifteen month study in approximately 120 children who are non-ambulatory with SMA between the ages of 2-12. The study will evaluate the efficacy and safety of a 12 mg dose of ISIS-SMN(Rx) with a primary endpoint of a change in the Hammersmith Functional Motor Scale-Expanded (HFMSE), a validated method to measure changes in muscle function in patients with SMA. Additional efficacy endpoints are also included in the study. In addition to the current Phase 3 clinical studies ENDEAR and CHERISH, Biogen Idec plans to conduct two additional ISIS-SMN(Rx) studies, which could begin in the first half of 2015: NURTURE will be a Phase 2 clinical study evaluating ISIS-SMNRx in up to 25 pre-symptomatic newborns that are genetically predisposed to the disease. EMBRACE will be a Phase 2 clinical study evaluating safety and exploratory efficacy of ISIS-SMNRx in approximately 20 patients with infantile or childhood-onset SMA. This study will bridge the gap in a small subset of patients that do not meet the age and inclusion criteria of the current Phase 3 studies ENDEAR and CHERISH.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISIS:US $59.49 USD +1.88

ISIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $30.95 USD +0.78
Acorda Therapeutics Inc $39.14 USD +0.74
Avanir Pharmaceuticals Inc $16.91 USD +0.01
Depomed Inc $15.54 USD +0.38
Prosensa Holding NV $18.76 USD +0.10
View Industry Companies

Industry Analysis


Industry Average

Valuation ISIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.9x
Price/Book 20.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 35.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISIS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at